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ABSTRACT
Orphan nuclear receptor Small Heterodimer Partner
(SHP; NR0B2) is a transcriptional corepressor of a
wide variety of nuclear receptors (NRs). Here, we
report that SHP recruits SIRT1, a class III histone
deacetylase, in an NR-specific manner to inhibit
transcriptional activity. SHP interacts and
co-localizes specifically with SIRT1 in vivo and in-
hibition of SIRT1 activity leads to a recovery from
the intrinsic repressive activity of SHP but not of
DAX1. Furthermore, we observed that SIRT1 does
not deacetylate SHP or LRH1. However, inhibition
of either SIRT1 or SHP significantly diminished the
repressive effect of SHP on LRH1 transactivity.
LRH1-mediated activation of CYP7A1 and SHP
gene transcription was significantly repressed by
both SHP and SIRT1 whereas inhibition of SIRT1
activity by inhibitors or dominant negative SIRT1 or
knockdown of SHP led to a significant release of this
inhibitory effect. ChIP assays revealed that SHP
recruits SIRT1 on LRH1 target gene promoters and
SIRT1 deacetylated template-dependent histone H3
and H4 to inhibit transcription of LRH1 target genes.
Finally, we demonstrated that inhibition of SIRT1
activity significantly reversed SHP-mediated inhib-
ition of bile-acid synthesis by LRH1 overexpression,
thereby suggesting a novel mechanism of SHP-
mediated inhibition of LRH1-dependent bile-acid
homeostasis via recruitment of SIRT1 histone
deacetylase protein.
INTRODUCTION
The orphan nuclear receptor small heterodimer partner
(SHP) protein is a unique member of the mammalian
nuclear receptor (NR) superfamily that lacks a conven-
tional DNA-binding domain but contains a putative
ligand-binding domain (1). SHP is highly expressed in
liver and predominantly functions as a transcriptional
corepressor of a wide array of NRs and transcription
factors (2,3). Recent studies indicate that SHP may
repress its targets via direct binding and/or interference
with the coactivator interaction interface of its target
NRs, or by antagonizing coactivator functions on NRs
via recruiting corepressor complexes that include histone
deacetylases (HDAC) 1, 3 and 6, Sin3A, and mammalian
histone methyltransferase (G9a) (2–6). SHP interacts and
regulates transcriptional activities of a large number of
NRs, including both ligand regulated receptors, such as
estrogen receptor (ER), GR, TR, AR, RAR and RXR
(retinoid X receptor), and orphan receptors, such as
LRH-1 (liver receptor homolog 1), HNF-4 (hepatic
nuclear factor 4), Nur77, ERR, CAR, LXR, PPAR and
thus, has been implicated in regulating diverse biological
activities, including cholesterol/bile acid (BA), lipid and
glucose/energy metabolic pathways (2,3).
The sirtuins are a highly conserved family of NAD-
dependent enzymes that regulate lifespan in lower organ-
isms (6–8). Recently, the mammalian sirtuins have been
connected to an ever widening circle of activities that
encompass cellular stress resistance, genomic stability,
tumorigenesis and energy metabolism. The founding
member of the sirtuin family, yeast Sir2 (silent informa-
tion regulator 2), was originally isolated in a screen for
silencing factors (8). To date, seven mammalian homologs
have been identiﬁed, with mammalian SIRT1 evolution-
arily closest to yeast Sir2. Cell biological studies have
further demonstrated diﬀerent subcellular compartments
for each family member, with SIRT1, SIRT6 and SIRT7
being nuclear proteins, SIRT3, SIRT4 and SIRT5 mito-
chondrial proteins, and SIRT2 being found both in the
nucleus and the cytoplasm, in a cell and tissue-dependent
context (6,7). SIRT1 is a nuclear class III deacetylase and
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deacetylating key transcription factors and coregulators
including LXRa, PPARg, FXR, PGC-1a, p300/CBP,
Foxo1, NF-kB and p53 (6–8). The NAD-dependent
deacetylase SIRT1 has been shown to regulate lipid and
carbohydrate metabolism and has been shown to extend
life span in several species (6–8).
SHP has been reported to play a key role in the negative
feedback regulation of cholesterol 7a hydroxylase gene
(CYP7A1) expression in the liver (10,11). This hepatic
enzyme catalyzes the ﬁrst and rate-limiting step of the
neutral pathway for the conversion of cholesterol into
BAs and thus plays a crucial role in enterohepatic
cholesterol-BA homeostasis (12). BAs also feedback-
regulate BA biosynthesis, where activated FXR induces
SHP gene expression, and SHP in turn inhibits LRH-1
and/or HNF4a activities on the BA response elements
(BAREs) of CYP7A1 promoter (10–12). Previous studies
have suggested that SHP mediates recruitment of
mSin3A-Swi/Snf and GPS2 (G protein pathway suppres-
sor 2), a subunit of the NR corepressor (N–CoR) complex,
to the CYP7A1 promoter, resulting in chromatin remodel-
ing and gene repression (5,6). A recent study has
demonstrated that SIRT1 knockdown in Type II
diabetes mellitus (T2DM) rat model is associated with sig-
niﬁcant induction of CYP7A1 gene expression, thereby
indicating a crucial role of SIRT1 in regulating hepatic
cholesterol metabolism via modulation of CYP7A1 tran-
scriptional activity (13). Although the key regulatory tran-
scription factors like FXR, LRH-1 and SHP, and
chromatin remodeling factor like SIRT1 have been
identiﬁed, the precise molecular events that occur at the
level of CYP7A1 promoter chromatin and gene repression
by a possible involvement of SHP and SIRT1 are yet to be
studied.
In the current study, we examined the mechanism of
regulation of BA homeostasis by SHP and SIRT1.
Using CYP7A1 gene, the key and rate-limiting enzyme
for BA homeostasis, as a major target, we studied the
repressive eﬀect of SHP and SIRT1 on LRH1-mediated
CYP7A1 transactivation at the native chromatin level
in HepG2 cells. We analyzed the eﬀect of SHP-SIRT1
on chromatin structure at the endogenous human
CYP7A1 promoter and the possible involvement of chro-
matin remodeling and histone de-acetylation. Here, we
report that SHP interacts with and recruits SIRT1
histone deacetylase to the endogenous human CYP7A1
promoter and represses LRH1 activity, thereby highlight-
ing a novel mechanism of SHP repressive action which
involves recruitment of novel factors on its targets and
also elucidating the role of SIRT1 in regulating LRH1
transactivation via SHP.
MATERIALS AND METHODS
Chemicals and antibodies
Nicotinamide (NAM) was obtained from Calbiochem and
all other chemicals were obtained from Sigma. Antibodies
used in this work were as follows: anti-Flag M2
(Stratagene), anti-HA (12CA5, Roche), anti-GST (Santa
Cruz), anti-SHP (H160, Santa Cruz), and anti-SIRT1,
anti-acetyl-histone H3 (Ac-H3), anti-acetyl-histone H4
(Ac-H4), anti-acetylated lysine (Ac-Lysine), anti-Myc,
anti-tubulin, anti-HDAC1 and anti-HDAC3 antibodies
were obtained from Cell Signaling Technology (CST).
The primary antibodies were used at a dilution ranging
from 1:200 to 1:1000 in western blot analysis, and at a
dilution of 1:200 in immunoprecipitation.
Plasmid and DNA construction
The plasmids of pCMV–b-gal, pSG5–HA–ERRg,
pcDNA3–HA–LRH1, pSG5–RARa, pcDNA3–HA–
Nur77, pcDNA3–HA–CAR, pcDNA3–ERa, pcDNA3–
HA–SHP, pcDNA3–Flag–SHP, pcDNA3–Flag–SIRT1,
pcDNA3–Myc–SIRT1, pcDNA3–Myc–SIRT1H363Y,
pcDNA3–HA–HNF4a, pEGFP–SHP (GFP–SHP),
Gal4–DBD, Gal4DBD–SHP, Gal4DBD–DAX1,
Gal4DBD–LRH1, the luciferase reporter constructs of
Sft4–Luc, RARE–Luc, NurRE–Luc, (NR)5–TK–Luc,
ERE–Luc, Gal4–TK–Luc (Gal4–Luc) and the human
SHP (hSHP–Luc) and the human CYP7A1 (hCYP7A1–
Luc) gene promoter luciferase constructs have been
described elsewhere (14–19). pcDNA3–Flag–SIRT6,–
SIRT7 has been described elsewhere (17). pEBG,
pEBG–SHP (1–260, full-length) constructs has been
described elsewhere (14,15). Deletion constructs of
pEBG–SHP (1–148), (1–92), (160–260) and (92–148)
were constructed from pEBG–SHP (1–260) construct
and pcDNA3–Flag–SIRT1 (1–499), (1–243), (243–747)
and (499–747) were constructed from pcDNA3–Flag–
SIRT1 (1–747, full length) construct and all constructs
were conﬁrmed by DNA sequencing. pSUPER and
pSUPER–siSHP constructs were kindly provided by Dr
J.K. Kemper. pSUPER–siSIRT1 and pSUPER–
siHDAC1 constructs had been described elsewhere (17).
Cell culture, transient transfection and luciferase assay
HepG2, HEK293T (293T) and HeLa cells were obtained
from the American Type Culture Collection. Maintenance
of cell lines and transient transfection assays were per-
formed using Lipofectamine2000 transfection reagent
(Invitrogen) according the manufacturer’s instructions as
described elsewhere (15). Brieﬂy, cells were transfected
with indicated reporter plasmids together with expression
vectors encoding various transcription factors or treated
with various chemicals. Total cDNA used for each trans-
fection was adjusted to 1mg/well by adding appropriate
amount of empty vector and pCMV–b-gal plasmid was
used as an internal control. Cells were harvested 40–48h
post-transfection for luciferase and b-galactosidase assays.
The luciferase activity was normalized to b-galactosidase
activity and expressed as relative luciferase units (RLU).
In vitro and In vivo GST pulldown assay,
coimmunoprecipitation (Co-IP) assay and
western blot analysis
In vitro and in vivo GST pull-down experiments were
performed as described elsewhere (15). In brief, 293T
cells were transfected in 60-mm dishes with the indicated
plasmids. After 48h of transfection, the whole-cell extracts
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used for in vivo GST pull-down assays followed by
western blot analysis with indicated antibodies. Co-IP
and western blot analysis were performed as described
previously (15). For Co-IP from tissue extracts, C57BL/
6J mice (n=3) were maintained ad libitum for 3days and
sacriﬁced. Liver tissue samples were used for Co-IP
assay. In western blot analysis of immunoprecipitated
proteins, conventional HRP-conjugated anti-rabbit IgG
was replaced with rabbit IgG TrueBlot (eBioscience,
#18-8816) to minimize/eliminate signal interference by
the immunoglobulin heavy and light chains.
Confocal microscopy
Confocal microscopy assays were carried out as described
elsewhere (15). In brief, the HeLa cells grown on
gelatin-coated coverslips were transfected with indicated
plasmids using Lipofectamine2000 transfection reagent
(Invitrogen) according to the manufacturer’s instructions.
After 24h of transfection, the cells were ﬁxed with 2%
formaldehyde followed by immunostaining and ﬁnally
the cells were subjected to observation by confocal
microscopy.
Preparation of recombinant adenovirus
For ectopic expression of the genes, adenoviral delivery
system was used. Brieﬂy, the cDNA encoding HA–
LRH1 was cloned into pAdTrack shuttle vector. Recom-
bination of AdTrack–CMV–HA–LRH1 with adenoviral
gene carrier vector was performed by transformation
into pretransformed AdEasy-BJ21 competent cells.
Adenoviruses (Ad) encoding GFP only (Ad–GFP), Ad–
SHP, Ad–siSHP, Ad–SIRT1 and Ad–SIRT1H355A were
described elsewhere (17,18).
RNA interference
Knockdown of SHP, SIRT1 and HDAC1 was performed
using the pSuper vector system (17,18). HepG2 cells were
transfected with siRNA constructs using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s in-
structions. siRNA treated cells were subjected to reverse
transcription PCR (RT–PCR) for conﬁrmation of
knockdown, and siRNA constructs were further used for
the transient transfection assay as indicated in the ﬁgure
legends.
Reverse transcriptase PCR and quantitative real-time
PCR analysis
Total RNA was isolated using the TRIzol reagent
(Invitrogen) according to the manufacturer’s instructions.
The mRNAs of CYP7A1 and SHP were analyzed by
reverse transcriptase PCR (RT–PCR) or quantitative
real-time PCR (qPCR) as indicated. DNA samples from
total RNA reverse transcription or from chromatin
immunoprecipitation (ChIP) assays served as the tem-
plates for qPCR experiments, which were performed
with QuantiTect SYBR GreenER PCR Kit (Qiagen) and
the Roter-Gene 6000 real-time PCR system (Australia) in
triplicate. Median cycle threshold values were determined
and used for analysis. ChIP data are presented as fold
enrichments over the values obtained with immunopreci-
pitations using control antibody (IgG). mRNA expression
levels were normalized to those of b-actin (ACTB). The
RT–PCR and qPCR primer sequences are available upon
request.
Chromatin immunoprecipitation assay
Formaldehyde cross-linking of cells, chromatin immuno-
precipitations (ChIPs), and real-time PCR analyses were
performed as described elsewhere (17). The immunopre-
cipitates were analyzed by qPCR. ChIP data are presented
as fold enrichments over the values obtained with
immunoprecipitations using control (IgG). Primer
sequences are available upon request.
BA analysis
After treating cells (as described in ﬁgure legend of
Figure 6B) in serum-free media, the media was collected
for analysis of BAs. Sep–Pak C18 reversed phase cart-
ridges (Waters Associates, Inc., Milford, MA) were used
for BA extraction from media as described elsewhere (20).
Total BA concentration was analyzed by enzymatic
3a-hydroxysteroid dehydrogenase method using total BA
assay kit (Bio-quant Inc., San Diego, CA) according to the
manufacturer’s instruction.
Statistical analysis
Student’s t-test was performed using GraphPad Prism 4.0
and results were considered to be statistically signiﬁcant
when P<0.05.
RESULTS
SHP diﬀerentially recruits SIRT1 or HDAC in an
NR-speciﬁc manner
SHP has been demonstrated to repress transcriptional
activity of several liganded and orphan NRs that include
LRH1, ERRg, RARa, Nur77, CAR and ERa (2,3). It has
also been shown that SHP recruits various chromatin re-
modeling factors including HDACs, Swi/Snf cofactor
complex, and GPS2 to exhibit transcriptional corepressor
activity on its targets (4–6,21). To elucidate the exact
mechanism involved behind involvement of SHP in chro-
matin remodeling and repression of transcriptional
activity of its targets we ﬁrst performed transient transfec-
tion assay with SHP and LRH1, ERRg, RARa, Nur77,
CAR and ERa in the presence or absence of inhibitors for
class I and II HDACs, TSA (trichostatin A) and class III
HDAC (SIRT1), NAM (Figure 1A–C). Interestingly, we
found that the repressive pattern of SHP and the recruit-
ment of HDACs (class I or II and class III) are dependent
on the target transcription factor involved. Our result in-
dicates that SHP-mediated repression of LRH1, ERRg
and RARa (Figure 1A) was not reversed by TSA,
whereas NAM treatment signiﬁcantly released the inhibi-
tory eﬀect of SHP on these transcription factors. On the
other hand, SHP-mediated repression of Nur77, CAR and
ERa was reversed upon TSA treatment, whereas NAM
Nucleic Acids Research, 2010,Vol.38, No. 14 4609showed no eﬀect on this repressive pattern (Figure 1B).
Next, RNA interference (siRNA) demonstrated that
knockdown of endogenous SIRT1 (by siSIRT1), but not
knockdown of HDAC1 (by siHDAC1), signiﬁcantly
released SHP-mediated repression of LRH1 transactivity
(Figure 1C, left). Similarly, like our previous observation
(Figure 1B), siHDAC1 cotransfection, but not siSIRT1
cotransfection, signiﬁcantly reversed SHP-mediated
repression of CAR transactivity (Figure 1C, right). RT–
PCR analysis of SIRT1 and HDAC1 gene expression con-
ﬁrmed a strong inhibitory eﬀect of siSIRT1 and siHDAC1
on SIRT1 and HDAC1 gene expression respectively
(Figure 1D). Overall, our initial results suggest that
SHP-mediated repression of target transcription factor
Figure 1. Utilization of diﬀerential repressive mechanism by SHP. Reporter assays (A–C) were performed as described in ‘Materials and Methods’
section. HepG2 cells were cotransfected with indicated reporter luciferase vectors (100ng each) and expression vectors (200ng each). b-gal expression
vector (100 ng) was used as an internal control for each transfected well. Cells were treated with RA (1mM; panel A, right) or E2 (10nM; panel B,
right) for 12h followed by TSA (100nM) or NAM (20mM) treatments for further 12h in the absence or presence of RA or E2. Cells were treated
only with TSA or NAM (panel A, B; left, middle) for 12h prior to the measurement of luciferase activity. (D) Eﬀect of siRNAs of siSIRT1 and
siHDAC1 on the expression of SIRT1 and HDAC1 respectively. HepG2 cells were transfected with pSuper- siSIRT1 or siHDAC1 or pSuper [control
(–)] and cells were collected for RNA isolation, by RT–PCR analysis, 72h post-transfection. b-actin (ACTB) gene expression was shown as control.
Data is representative of at least three independently performed experiments.
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HDAC (class I and II histone deacetylase) or SIRT1
(class III histone deacetylase).
SHP interacts and colocalizes with SIRT1 in vivo
Since cell biological studies have demonstrated that
among sirtuins family members (SIRT1-7), SIRT1,
SIRT6 and SIRT7 are localized predominantly/exclusively
in the nucleus (7–9), we next analyzed the interaction
pattern of SIRT1, SIRT6 and SIRT7 with NR SHP
(Figure 2A). In vivo GST pull-down assay demonstrated
that exogenous SHP interacted speciﬁcally with exogenous
SIRT1 (left panel) but not with either SIRT6 or SIRT7
(right panel). To reconﬁrm the interaction between
SHP and SIRT1, we performed coimmunoprecipitation
(Co-IP) assay to detect endogenous interaction between
SHP and SIRT1 in human HepG2 cells and C57BL/6J
mouse liver extracts (Figure 2B). Co-IP with speciﬁc
antibody for SHP and SIRT1 detected endogenous inter-
action and complex formation between SIRT1 and SHP in
both HepG2 cells (left panel) as well as in mouse liver
tissue extracts (right panel). Next, to investigate whether
SHP and SIRT1 are co-localized in the same subcellular
compartment, we performed confocal microscopy in HeLa
cells (Figure 2C). Our results demonstrated that both SHP
and SIRT1 are co-localized in the nucleus as can be
evidenced from the merged image. Collectively, these
results demonstrate that SHP interacts and co-localizes
with SIRT1 in vivo.
Interaction domain mapping of SHP and SIRT1
Next we attempted to ascertain the interaction domain
between SHP and SIRT1 using in vivo GST pull-down
assays (Figure 3). The schematic diagrams (Figure 3A
and B, top) depict the domains into which both SHP
and SIRT1 protein can be broadly divided. First, using
Figure 2. SHP interacts and colocalizes with SIRT1. (A and B) In vivo interaction of exogenous SHP with exogenous SIRT1, SIRT6 and SIRT7 (A).
293T cells were cotransfected with Flag–SIRT1 (panel A, left), Flag–SIRT6 or Flag–SIRT7 (panel A, right) and pEBG–SHP (GST–SHP) or with
pEBG (GST) alone. The complex formation (GST puriﬁcation) and the amount of Flag–SIRT1, Flag–SIRT6 or Flag–SIRT7 used for in vivo binding
assay (cell lysate) were determined by western blot using indicated antibodies. In vivo interaction of endogenous SIRT1 with endogenous SHP (B).
Co-immunoprecipitation assays were performed with cell extracts from HepG2 cells (panel B, left) and C57BL/6J mouse liver tissue extracts (panel B,
right). Endogenous SIRT1 or endogenous SHP was immunoprecipitated with SHP or SIRT1 respectively, and were analyzed by western blot using
indicated antibodies. (C) Colocalization of SHP with SIRT1. HeLa cells grown on coverslips in 12-well plates were transfected with expression
vectors encoding GFP–SHP and Flag–SIRT1 (200ng each). For the immunoﬂuorescence of ﬁxed cells, Flag–SIRT1 protein was immunostained with
mouse monoclonal anti-Flag antibody and visualized with dye Alexa Fluor 488-conjugated anti-mouse antibody. The cell images were captured
under 400 magniﬁcations. Data is representative of atleast three independently performed experiments.
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found that SHP interacted with the C-terminus domain
of SIRT1 protein (Figure 3A, bottom and C), suggesting
that SIRT1 C-terminus domain is necessary for inter-
action with SHP. Next, we used diﬀerent SHP mutant
constructs and our results demonstrated that the
N-terminus domain of SHP was responsible for inter-
action with SIRT1 protein (Figure 3B, bottom and D).
Overall, these results demonstrated that the amino-acid
residues 499–747 of SIRT1 protein, corresponding to the
C-terminus domain, is required for interaction with SHP
whereas the amino-acid residues 1–92 of SHP protein is
suﬃcient to interact with SIRT1.
SHP recruits SIRT1 to inhibit LRH1
transcriptional activity
NR DAX-1 is the closest relative to SHP in the NR family
and both share considerable structural and functional
similarities and have been previously demonstrated to
possess intrinsic repressive eﬀect (2,3). Therefore, we
tried to investigate whether the involvement of SIRT1 is
speciﬁc for SHP-mediated transcriptional repressive
activity. Using Gal4-fusion proteins of SHP and DAX-1,
we performed transient transfection assays in the absence
or presence of siSIRT1 and SIRT1 inhibitor NAM
(Figure 4A). Both SHP and DAX-1 showed signiﬁcant
repression of basal Gal4 luciferase reporter (Gal4–Luc)
transactivity. However, upon cotransfection with
siSIRT1 (left) or treatment with NAM (right) we found
that the intrinsic repressive eﬀect of SHP was signiﬁcantly
reversed whereas no reversal of DAX-1 intrinsic repressive
eﬀect was observed in any of those treatments. These
results suggest that SIRT1 plays an important role in
mediating the repressive eﬀect of SHP speciﬁcally.
Previous studies have shown that SIRT1 interacts and
deacetylates several transcription factors (7–9). Thus, we
were interested to know whether the interaction of SIRT1
with SHP (Figure 2) has any eﬀect on the acetylation
status of SHP protein. We performed Co-IP assays to de-
termine the acetylation/deacetylation level of SHP by
SIRT1 (Figure 4B) using speciﬁc antibody to detect
acetylated lysine residues (Ac-Lysine). Interestingly, no
signiﬁcant change in the acetylation/deacetylation level
Figure 3. Interaction domains of SIRT1 and SHP. Schematic representation of structure of SIRT1 (A, top) and SHP protein (B, top) with
amino-acid numbers indicated. HepG2 cells were co-transfected with Flag–SIRT1 mutants and pEBG alone or pEBG–SHP (A and C) or with
pEBG alone or pEBG–SHP mutants and Flag–SIRT1 (B and D) as indicated. Protein interactions were examined via in vivo GST pull-down assay.
The top and middle panels (GST puriﬁcation) show GST beads-precipitated Flag–SIRT1 and GST fusions, respectively. The bottom panel shows the
protein expression levels of Flag–SIRT1 in cell lysates. Data is representative of atleast three independently performed experiments.
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indicating that SIRT1 may not directly aﬀect the acetyl-
ation/deacetylation status of SHP protein.
Next, we tried to ascertain the involvement of SHP
and SIRT1 on LRH1-mediated transcriptional activity
by transient transfection assay using Gal4–luc reporter
and Sft4–luc (containing multiple LRH1/SF-1-binding
elements) reporter constructs (Figure 4C and G).
Gal4-fused LRH1 protein signiﬁcantly activated the
reporter luciferase activity and cotransfection with SHP
Figure 4. SHP recruits SIRT1 to inhibit LRH1 transactivation. Reporter assays (A, C and G) were performed as described in ‘Materials and
Methods’ section. HepG2 cells were cotransfected with indicated expression vectors (200ng each) and Gal4–Luc (A and C) or Sft4–Luc (G) luciferase
reporter vector (100ng). b-gal expression vector (100ng) was used as an internal control for each transfected well. Cells were treated with NAM
(20mM), resveratrol (100nM) or piceatannol (20mM) for 12h prior to the measurement of luﬁcerase activity. Data is representative of atleast three
independently performed experiments and shown as mean±SD; *P<0.05 using Student’s t-test. (B, D and F) HepG2 cells were cotransfected with
Flag–SHP and Myc–SIRT1 (B) or HA–LRH1 (D), HA–HNF4a (F) and Flag–SIRT1. Forty-eight hours post transfection, Flag–SHP, HA–LRH1 or
HA–HNF4a were immunoprecipitated and analyzed by western blot analysis using indicated antibodies. Data is representative of atleast three
independently performed experiments. (E) In vitro GST pull-down assays.
35S-radiolabeled SIRT1 protein (upper panel) or
35S-radiolabeled SHP
protein (lower panel) were incubated with GST, or GST–LRH1 fusion proteins. The input lane represents 10% of the total volume of in vitro-
translated proteins used for binding assay. Protein interactions were detected via autoradiography.
Nucleic Acids Research, 2010,Vol.38, No. 14 4613dramatically repressed this transactivation (Figure 4C,
left). The repressive eﬀect of SHP was signiﬁcantly
reversed by either cotransfection with siSIRT1 expression
vector or upon treatment with SIRT1 inhibitor NAM.
NAM treatment or siSIRT1 cotransfection, in the absence
of overexpression of SHP, also signiﬁcantly activated
Gal4–LRH1 mediated transactivity. Conversely, treat-
ment with SIRT1 activators, Resveratrol or Piceatannol,
showed similar repressive eﬀect on Gal4–LRH1 transacti-
vation (right), similar to SHP. Cotransfection with siSHP
expression vector dramatically reversed the strong repres-
sive eﬀect of SIRT1 activators on Gal4–LRH1 transacti-
vation. We further conﬁrmed these eﬀects in Sft4–luc
reporter constructs (Figure 4G) using wild-type SIRT1
and a deacetylase-defective SIRT1 (H363Y) mutant (17)
on LRH1 transactivation (left). Overexpression of SIRT1
alone inhibited LRH1 activity (70–80%) which was sig-
niﬁcantly released by siSHP overexpression. However, the
dominant negative SIRT1 mutant SIRT1H363Y showed
no observable eﬀect of LRH1 transactivity, thereby sug-
gesting that SIRT1 deacetylase activity is needed for the
repression of LRH1 by SHP. Finally, endogenous SIRT1
inhibition by siSIRT1 or NAM signiﬁcantly recovered
LRH1 activity from SHP repressive eﬀect in Sft4–luc
(right), similar and consistent with our previous observa-
tions (Figure 4C, left).
SHP plays a well-documented role in inhibiting LRH1-
mediated transcriptional activation (10–12). Knockdown
of endogenous SIRT1 has also been demonstrated to
increase LRH1 gene transcription (13). Consistent with
these reports, our earlier observations (Figure 1A and C,
left) suggest that SIRT1 is involved, at least in part, in
the SHP-mediated repression of LRH1 transcriptional
activity. Therefore, initially we investigated the acetyl-
ation/deacetylation level of LRH1 protein by SIRT1
(Figure 4D and F). Co-IP assay results using
cotransfection of LRH1 or HNF4a (positive control) in
the absence or presence of SIRT1 clearly demonstrated
that SIRT1 has no observable eﬀect on the acetylation/
deacetylation status of LRH1 protein (Figure 4D) but
physically interacts with and deacetylated HNF4a
protein (Figure 4F). Interestingly, we could not detect
SIRT1 protein after immunoprecipitation with anti-HA
antibody (for HA–LRH1), suggesting that LRH1 does
not physically interact with SIRT1. Additionally, we per-
formed in vitro GST pull-down assays using
35S-labeled
in vitro translated SHP and SIRT1 proteins and
GST-fused LRH1 protein and our results demonstrated
that LRH1 directly interacts with SHP but not with
SIRT1(Figure 4E).Taken together, these results indicate
that SHP recruits SIRT1 and utilizes SIRT1 deacetylase
activity to inhibit LRH1 mediated transcriptional
activation.
SIRT1 potentiates SHP-mediated repression of
LRH1 target gene transcription
SHP is a key player in hepatic BA biosynthesis via
negative regulation of CYP7A1 mainly by repression of
LRH1 (10–12). LRH1 is also a well known activator of
SHP gene transcription (10,11), thereby, leading to an
auto-regulatory loop of gene regulation by SHP. Thus,
we attempted to elucidate the role of SHP–SIRT1 inter-
action in the inhibition of LRH1 target gene transcription
(Figure 5). Using human CYP7A1 and SHP gene
promoter luciferase constructs, we performed transient
transfection assay in the absence (Figure 5A) or presence
of LRH1 overexpression (Figure 5B). The basal promoter
activity was signiﬁcantly increased upon endogenous
knockdown of SHP (by siSHP) or by SIRT1 knockdown
using siSIRT1 or NAM treatment (Figure 5A), thereby
suggesting the involvement of both SHP and SIRT1 in
transcriptional repression of CYP7A1 and SHP gene
promoter activity, possibly via inhibition of several tran-
scription factors, including LRH1, which are common
targets of both SHP and SIRT1, like HNF4a. Next, we
tried to evaluate speciﬁcally the LRH1-mediated eﬀect on
these gene promoters and the role of SHP and SIRT1.
LRH1 overexpression led to a signiﬁcant activation of
these gene promoters (5–7-fold). Both SHP and SIRT1
independently inhibited the promoter transactivation by
LRH1 and endogenous knockdown of SIRT1 or SHP sig-
niﬁcantly reversed the repressive eﬀect of SHP or SIRT1,
respectively (Figure 5B). Expectedly, repression of
CYP7A1 and SHP promoter transactivation by SHP
overexpression was released upon treatment with
NAM, and resveratrol-mediated inhibition of the pro-
moter activities was reversed by siSHP cotransfection
(Figure 5B).
Next, we examined the changes in the mRNA levels
of CYP7A1 and SHP genes under basal condition
(Figure 5D) or using adenovirus (Ad) LRH1 infection
with combinatorial treatments of either Ad–SHP infection
in absence or presence of Ad–SIRT1H355A (dominant
negative SIRT1) (17) or NAM as well as Ad–SIRT1 in-
fection with or without Ad–siSHP infection (Figure 5E).
First, we conﬁrmed the protein expression of LRH1,
SIRT1 and SHP after the respective adenovirus infection
(Figure 5C). Under basal condition, Ad–SHP and Ad–
SIRT1 signiﬁcantly repressed CYP7A1 and SHP gene
expression and these repressive eﬀects were recovered
considerably upon co-infection with Ad–SIRT1H355A
or NAM treatment (with Ad–SHP) as well as by Ad–
siSHP (with Ad–SIRT1) (Figure 5D). These results dem-
onstrate a similar trend to the promoter activity observed
in Figure 5A and suggests the possibility of repressive
eﬀect of SHP and SIRT1 on various transcription
factors which are known to induce CYP7A1 and SHP
gene expression. Therefore, we attempted to investigate
the eﬀect of SIRT1 and SHP in LRH1-speciﬁc induction
of CYP7A1 and SHP gene expression (Figure 5E). RT–
PCR analysis (Figure 5E, top) and qPCR quantiﬁcation
(Figure 5E, bottom) results clearly demonstrated the in-
duction of CYP7A1 and SHP mRNA levels after Ad–
LRH1 infection. Subsequently, Ad–SHP infection led to
a dramatic decrease in CYP7A1 and SHP mRNA levels.
Ad–SIRT1H355A infection or NAM treatment released
the Ad–SHP mediated repression of CYP7A1 as well as
SHP mRNA level. Similarly, Ad–SIRT1 co-infection with
Ad–LRH1 signiﬁcantly repressed mRNA level of both
CYP7A1 and SHP genes and knockdown of endogenous
SHP levels by Ad–siSHP led to a recovery in the CYP7A1
4614 Nucleic Acids Research, 2010,Vol.38, No. 14mRNA expression but, had no observable eﬀect on SHP
mRNA level. Taken together, these results suggest that
SHP and SIRT1 works co-operatively to inhibit
LRH1-mediated target gene induction, though, under
basal conditions the role of various other transcription
factors which are reported to be common target of both
SHP and SIRT1, like HNF4a, cannot be ruled out
completely.
Figure 5. Involvement of SHP and SIRT1 in the repression of LRH1 target genes. Reporter assay (A and B) was performed as described
in ‘Materials and Methods’ section. HepG2 cells were cotransfected with luciferase constructs of human CYP7A1 (hCYP7A1–Luc) and human
SHP (hSHP–Luc) gene promoters (100ng each) and indicated expression vectors (200ng each). b-gal expression vector (100ng) was used as an
internal control for each transfected well. Cells were treated with NAM (20mM) or resveratrol (Resv, 100nM) for 12h prior to the measurement of
luﬁcerase activity. (C) HepG2 cells were transfected with pcDNA3 only (–) or pcDNA3–HA–LRH1 (400ng each) or infected with indicated
adenovirus vectors (50 MOI) for 36–72 h and cells extracts were for western blot analysis using indicated antibodies. (D and E) HepG2 cells
were treated with indicated adenovirus vectors (50 MOI) for 36–72h. Twelve hours prior to RNA extraction cells were treated with NAM (20mM,
lane 3 and 6) and total RNA isolated were used for RT–PCR (top) and qPCR (bottom) analysis of CYP7A1 and SHP gene expression. b-actin
(ACTB) gene expression was shown as control. Data is representative of at least three independently performed experiments and shown as
mean±SD; *P<0.05 using Student’s t-test.
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Since gene repression is often associated with decreased
histone acetylation (22), we determined whether the re-
cruitment of SIRT1 by SHP results in template-associated
histone (H3 and/or H4) deacetylation at the LRH1 tar-
get gene promoters (CYP7A1 and SHP) by using ChIP
assays (Figure 6A). Adenoviral overexpression of LRH1
increased acetylation of H3 (Ac–H3) and H4 (Ac–H4)
on the LRH1-responsive region of CYP7A1 and SHP
promoters. This H3–H4 acetylation was severely com-
promised upon Ad–SHP or Ad–SIRT1 infection and the
decrease of histone acetylation was signiﬁcantly recovered
upon treatment with Ad–SIRT1H355A or NAM on Ad–
SHP infected cells or by Ad–siSHP infection on Ad–
SIRT1 infected cells. No signal was detected after PCR
ampliﬁcation of control regions of either CYP7A1 or SHP
promoters which are non-responsive to LRH1 occupancy
and transactivation (data not shown). Additionally,
we performced similar set of experiments in absence
of Ad–LRH1 overexpression to assess the basal promoter
acetylation status (Supplementary Figure S1A). Decreased
acetylation of H3 and H4 were observed upon Ad–SHP
and Ad–SIRT1 infection and this decrease was recovered
Figure 6. SHP recruits SIRT1 deacetylase to inhibit LRH1-mediated target gene activation. (A) The recruitment of SIRT1 by SHP on CYP7A1 (left)
and SHP (right) gene promoters is associated with template-associated histone (H3 and H4) deacetylation. HepG2 cells were treated with indicated
adenovirus vectors (50 MOI) for 36–72 h. Twelve hours prior to preparation of cell lysates for ChIP assay cells were treated with NAM (20mM).
Chromatin fragments were prepared and immumoprecipitated with the indicated speciﬁc antibodies. DNA fragments covering BARE-I and BARE-II
element on CYP7A1 (left) and LRH1-binding regions on SHP promoter (right) were PCR-ampliﬁed as described in the ‘Materials and Methods’
section. (B) HepG2 cells were infected with adenovirus vectors as indicated for 36–72h and for the last 12h cells were treated with NAM (20mM) as
indicated. Media was collected for total bile synthesis using Sep-Pak cartridges as described in the ‘Materials and Methods’ section. Data is
representative of atleast three independently performed experiments and shown as mean±SD; *P<0.05 using Student’s t-test. (C) HepG2 cells
were infected with adenovirus vectors as indicated for 36-72 h and for the last 12h cells were treated with BA (50mM) as indicated and total RNA
isolated were used for RT–PCR (top) and qPCR (bottom) analysis of CYP7A1 mRNA level. b-actin (ACTB) gene expression was shown as control.
Data is representative of atleast three independently performed experiments and shown as mean±SD; *P<0.05 versus untreated, **P<0.05 versus
BA treatment and
#P<0.05 versus adenovirus infected lanes alone, using Student’s t-test. (D) Schematic representation of an auto-regulatory loop
controlling the expression of SHP by LRH1 and inhibition of LRH1 activity by SHP itself via recruitment of SIRT1 histone deacetylase activity on
target gene promoters of LRH1.
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knockdown of SHP, suggesting the involvement of
several other transcription factors regulating CYP7A1
and SHP gene promoters, along with LRH1, that are
targets of SHP and/or SIRT1. A previous report
demonstrated the co-occupancy of HDAC1, HDAC3
and SHP on CYP7A1 and SHP gene promoter under
BA-treated condition (5). Therefore, we investigated the
occupancy of HDAC1 and 3 on CYP7A1 gene promoter
under our experimental conditions (Supplementary Figure
S1B). Interestingly, both HDAC1 and 3 were detected in
these conditions, though various combinatorial treatments
showed no signiﬁcant change in the occupancy status (fold
occupancy) of either HDAC1 or 3, thereby suggesting
them to be enzymatically inactive under these conditions
and a promoter-speciﬁc activity of HDACs in general.
Collectively, these results demonstrate that the recruit-
ment of SIRT1 by SHP on the LRH1 target gene pro-
moters stimulates deacetylation of template-associated
histone H3 and H4 and this chromatin remodeling phe-
nomenon ultimately leads to repression of LRH1 target
gene expression by SHP in a SIRT1-dependent manner.
To conﬁrm the eﬀect of SIRT1 recruitment by SHP
on total BA synthesis in the absence or presence of
LRH1 overexpression, we analyzed the cell culture
media for BA synthesis (Supplementary Figure S1C and
Figure 6B). In the absence of LRH1 overexpression, Ad–
SHP mediated repression of basal BA synthesis was sig-
niﬁcantly recovered by SIRT1 inhibition (using NAM
or Ad–SIRT1H355A) (Supplementary Figure S1C).
Overexpression of LRH1 resulted in a signiﬁcant
increase in total BA synthesized and SHP overexpression
led to 50% decrease in the total bile synthesis.
Overexpression of dominant negative SIRT1 or SIRT1
inhibitor NAM resulted in a signiﬁcant recovery in the
total BA synthesis in the culture media, suggesting that
SHP and SIRT1 co-ordinates the negative regulation of
BA synthesis. BAs are known to be a negative regulator of
CYP7A1 gene expression (10–12). Therefore, to evaluate
the importance of SIRT1 in BA metabolism and CYP7A1
gene repression, we treated cells with BA (Figure 6C). BA
mediated repression of CYP7A1 gene expression was
recovered to a considerable extent by overexpression of
Ad–SIRT1H355A or Ad–siSHP. Combinatorial over-
expression of dominant negative SIRT1 and siRNA
SHP recovered CYP7A1 mRNA level to a signiﬁcant
extent (80%) after BA treatment, thereby conﬁrming a
key role of SIRT1, along with SHP in regulating CYP7A1
gene expression and subsequently BA metabolism.
DISCUSSION
In the current study, we demonstrated that SHP diﬀeren-
tially recruits HDACs of class I (HDAC1) or class III
(SIRT1) in a NR speciﬁc manner and inhibits transcrip-
tional activity of these NRs. We also evidenced in vivo
exogenous and endogenous interaction and colocalization
of SIRT1 with SHP in the nucleus. The speciﬁcity of inter-
action between SHP and SIRT1 was further conﬁrmed
from the observations that neither SIRT6 nor SIRT7,
two other nuclear-localized members of the sirtuins
family, interacted with SHP. On the other hand, unlike
SHP, the intrinsic repressive eﬀect of NR DAX1, the
closest family member to SHP, was not dependent on
SIRT1-recruitment to its target transcription factors.
Interestingly, neither SHP nor its target transcription
factor and NR LRH1 were directly deacetylated by
SIRT1. However, we demonstrated that SHP-mediated
repression of LRH1 transcriptional activity as well as in-
hibition LRH1 target gene promoter activity and mRNA
levels were signiﬁcantly dependent on SIRT1 deacetylase
activity. Detailed elucidation of the molecular mechanism
of SHP–SIRT1 eﬀect suggested template-dependent chro-
matin remodeling of LRH1 target gene promoters by SHP
via utilization of SIRT1 deacetylase activity. Overall, our
current ﬁnding reveals a novel molecular mechanism
employed by nuclear corepressor SHP to inhibit transcrip-
tional activity of its target transcription factor and
provides evidences of a new role of SIRT1 in working
concertedly with NRs and aﬀecting chromatin remodeling
in target gene promoters.
Histone acetylation and deacetylation are essential
factors in modifying chromatin structure and regulating
gene expression in eukaryotes (2,3). Many studies have
demonstrated that methylation of H3 lysine9 (H3–K9) is
associated with transcriptionally inactive chromatin
(23,24). Recently, it was also reported that SHP could
interact not only with the G9a H3–K9 methyltransferase
but also with lysine 9-methylated histone 3, pointing out
the role of SHP in negative regulation of gene expression
via chromatin remodeling (21). In our study, we initially
observed that the inhibition of transcriptional activity by
SHP is via utilization of both class I HDAC recruitment
(as in case of Nur77, CAR and ERa) as well as class III
HDAC, i.e., SIRT1 recruitment (as in case of LRH1,
ERRg and RARa). This interesting NR-speciﬁc recruit-
ment of diﬀerent class of HDACs is a novel phenomenon
observed for SHP and is reminiscent of a previous report
from our group demonstrating similar NR-speciﬁc repres-
sion mechanism by SMILE (CREBZF), a SHP-interacting
protein (14, 15 and 17). Interaction of SHP speciﬁcally
with SIRT1 and not with any other nuclear-localized
SIRT family members (SIRT6 and SIRT7) further
enhances the signiﬁcance of SIRT1 recruitment by SHP
to target transcription factors. We further observed that
SIRT1 contributes signiﬁcantly to the intrinsic repressive
eﬀect of SHP, but not for DAX1. This further underlines
the importance of SIRT1 in SHP-mediated repression of
transcription factors. Though inhibition of SIRT1 activity
by NAM was not completely able to recover the intrinsic
repressive eﬀect of SHP exerted on Gal4DBD fused
protein alone, however, involvement of various other
corepressor complexes with SHP which are
TSA-sensitive proteins (class I and II HDACs, mSin3A
and GPS2) should be taken into consideration. Along
with this hypothesis, a recent report demonstrated the
interaction between SHP and a non-HDAC protein,
EID1 and the mechanism of action of EID1 was via
antagonizing the CBP-dependent coactivator functions
(25). Previous report from our group also suggested the
role of helices H6 and H7 in transcriptional repression
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novel repression strategy utilized by SHP via interaction
with and recruitment of SIRT1 and may explain the
target-speciﬁc gene regulation by SHP.
Among mammalian Sirtuins, SIRT1 is the closest
homolog to yeast Sir2p and the best studied by far
(7–9). The ﬁrst noteworthy feature about the mechanism
of action of SIRT1 is that while the majority of its
associated functions are exerted through chromatin,
however, as opposed to other HDACs, SIRT1 is a coord-
inator of simultaneous events, evidenced by its capacity to
bind myriad factors and to target for deacetylation of the
histone marks H4K16Ac and H3K9Ac, as well as tran-
scription factors, and even other enzymes such as the
histone acetyltransferase p300 or the histone
methyltransferase Suv39h1. Sirtuins in general and
SIRT1 in particular, do not bind directly to chromatin,
but are instead recruited by speciﬁc factors (7–9).
Consistent with these features of SIRT1, our study dem-
onstrates that NR corepressor SHP recruits SIRT1 to
inhibit LRH1, along with possibly ERRg and RARa,
transactivation (as we observed in Figure 1A). Previous
reports investigating the role of SIRT1 have demonstrated
that it can interact with and deacetylate speciﬁc transcrip-
tion factors, thereby modulating their ability to activate or
repress gene transcription (7–9,27–30). Among NRs,
SIRT1 has been shown to directly deacetylate and
activate LXRa (27) whereas deacetylation of HNF4a by
SIRT1 leads to deactivation of HNF4a (28). A recent
study demonstrated that FXRa is dynamically
deacetylated/acetylated by SIRT1 and p300 to modulate
the activity of FXRa under various metabolic states (29).
SIRT1 has also been demonstrated to interfere with the
activity of PPARg by binding to the corepressors NCoR
and SMRT (30). In that context, our ﬁndings, for the ﬁrst
time, suggest recruitment of SIRT1 by a NR corepressor
(SHP) in a NR-speciﬁc manner, leading to template-
dependent histone H3 and H4 deacetylation without
direct deacetylation of either SHP or the transcription
factor (LRH1) itself. However, SHP is also known to
recruit HDACs or other non-HDAC cofactors (like
EID1) to repress transcriptional activation of its targets
(4–6,21). Therefore, an obvious question is how SHP dif-
ferentially recruits these chromatin remodeling complexes
to ultimately repress transcription. A plausible explan-
ation behind this interesting phenomenon might be
the conformational changes that may occur during the
interaction of SHP with various NRs, which might
decide the complex formation of SHP with a wide
variety of chromatin remodeling complex. In fact, our
results demonstrate that HDAC1 and 3 could be
detected in the chromatin complex, but are irresponsive
to the CYP7A1-speciﬁc LRH1–SHP–SIRT1 complex,
thereby suggesting that the HDAC activity might be
a promoter-speciﬁc phenomenon. Co-cyrstallization of
SHP–NR complexes in future studies will be able to
provide with a detailed insight into this phenomenon.
On the other hand, SHP-mediated inhibition of LRH1
transactivity has been previously attributed to mSin3A
and Swi/Snf complex formation with SHP as well as
GPS2–SHP interaction (5,6). Our ﬁndings suggest that
SHP recruits SIRT1 to inhibit LRH1 transactivity. The
possibility of recruitment of various chromatin remodeling
complexes to the same NR by SHP can be explained by
taking into account the upstream cell signaling pathways
involved in regulating SHP gene expression and protein
stability. In that context, BAs have been shown to regulate
SHP gene expression and protein stability via ERK-
signaling pathway (29), whereas the kinase LKB1, a
tumor suppressor that is required for AMPK activation
under energy-deﬁcient conditions, is regulated by SIRT1
(8) and AMPK in turn has been reported by our group to
induce SHP gene expression (18,31–33) and may also
aﬀect post-translational modiﬁcations of SHP protein.
Previous studies showed that along with the BA-
activated NR FXR, LRH1 activates SHP gene promoter
and transcription (10–12). The BA-induced SHP then
interacts with and inhibits LRH1 and/or HNF4a, bound
to the BA response element (BARE) in the CYP7A1
promoter, resulting in a negative feedback auto-regulatory
loop (10–12). A recent study demonstrated that Brm or
Brg-1 ATPases (contained in the Swi/Snf complexes) play
an important role in regulation of BA metabolism under
physiological conditions by FXR and SHP. Brg-1 inter-
acted with FXR and enhanced FXR-mediated transacti-
vation of SHP, whereas Brm interacted with SHP and
enhanced SHP-mediated repression of CYP7A1 and
auto-repression of SHP (34). SIRT1 is critically involved
in liver metabolic regulation (7–9,13) and a recent report
suggests that SIRT1 knockdown increases levels of
CYP7A1 mRNA (13). Consistent with these reports, our
current observations suggests that recruitment of SIRT1
by SHP leads to the decreased promoter activity and
mRNA levels of LRH1-induced CYP7A1 and SHP
gene. Interestingly, our results also demonstrate that BA
mediated repression of CYP7A1 gene expression was sig-
niﬁcantly recovered by inhibition of SIRT1 activity.
Thereby, it suggests the involvement of a novel cofactor,
SIRT1, in the negative feedback autoregulatory loop of
SHP gene (Figure 6C). Recruitment of SIRT1 deacetylase
activity by SHP to regulate BA homeostasis as well its
own gene expression therefore provides with a new mech-
anism of tight control exerted by SHP in liver metabolic
pathways. Overall, our current ﬁndings provide insight
into a novel chromatin remodeling strategy utilized by
SHP and from a broader perspective it may be relevant,
not only for the regulation of cholesterol and BA metab-
olism, but also for glucose homeostasis and other import-
ant biological processes in which both SHP and SIRT1
plays well-documented key regulatory roles.
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